Nipro Diag/Triv Patent-Cliff Exposure & CMS Drug Spending Portfolio

Nipro Diag/Triv (US): 8 reconciled FDA prescription therapies, $6.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$6.2M
2024 Medicare Part D Spend$6.1M
2024 Medicaid Spend$191K
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel